News | October 31, 2011

New Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT

New Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT

October 31, 2011 – The Breast journal published new data from a prospective study conducted at the Seoul National University College of Medicine in Korea that shows positron emission mammography (PEM) has a higher sensitivity for tumor detection compared with whole-body positron emission tomography (PET)/ computed tomography (CT) when using both visual as well as quantitative analysis. These results were particularly striking and significant for smaller-sized tumors (less than 2 cm), likely due to the improved spatial resolution offered by PEM. This demonstrates PEM's clinical utility in being able to more effectively diagnosis early stage cancer.

According to recent journal articles, the sensitivity of PET/CT is limited, especially for low-grade and small tumors. Most PET/CT scanners currently provide a spatial resolution at 5 mm or greater, thus limiting PET/CT's ability to depict small-sized tumors such as invasive lobular carcinoma or ductal carcinoma in situ. This study provides a direct comparison within the same patient population.

A total of 113 breast lesions from 101 patients with a mean tumor size of 2.2 cm, were included in the analysis. The patients underwent PEM with FDG and whole-body PET/CT before surgical resection. The images were then analyzed visually and quantitatively using the tumor-to-normal tissue uptake ratio (TNR) with a cutoff of 2.5 or greater. The tumors were classified into 4 groups based on size using pathology measurements prior to detection sensitivity analysis for PEM and PET/CT. In visual analysis, the overall sensitivity of PEM was 95 percent, which was significantly higher than the 87 percent sensitivity found for PET/CT; ( p=0.004). In addition, the TNR of PEM was significantly higher than that of PET/CT in small tumors (<1 cm; p=0.005 and <2 cm; p<0.001).

PEM is the breast application of the Naviscan high-resolution PET scanner, which both can localize as well as characterize the metabolic activity of a lesion. PEM uses parallel photon detectors in a configuration similar to mammography with breast immobilization, not compression. It is the only U.S. Food and Drug Administration (FDA)-cleared, CE Certified 3-D molecular breast imaging (MBI) device on the market. The metabolic view assists physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.

For more information: www.naviscan.com

 

Related Content

Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...